0000899243-18-018026.txt : 20180625 0000899243-18-018026.hdr.sgml : 20180625 20180625211402 ACCESSION NUMBER: 0000899243-18-018026 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180625 FILED AS OF DATE: 20180625 DATE AS OF CHANGE: 20180625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Onyx Therapeutics, Inc. CENTRAL INDEX KEY: 0001744260 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 18918140 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: 805-447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 18918141 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER NAME: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-25 1 0001645666 Kezar Life Sciences, Inc. KZR 0001744260 Onyx Therapeutics, Inc. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 0 0 1 0 0000318154 AMGEN INC ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 0 0 1 0 Common Stock 2018-06-25 4 C 0 1121384 A 1121384 D Series A Redeemable Convertible Preferred Stock 2018-06-25 4 C 0 1121384 0.00 D Common Stock 1121384 0 D As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock. These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx. Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock. /s/ Andrea A. Robinson, Assistant Secretary and Associate General Counsel on behalf of Onyx Therapeutics, Inc. and Amgen Inc. 2018-06-25